| 摘要 |
A solid dispersion is provided to improve bioavailability of revaprazan by increasing solubility of the revaprazan, improve stability and formulation processability by decreasing adhesiveness and agglutination properties of the revaprazan and avoid any residual solvent and toxicity problems caused by using an organic solvent by using water as a medium for preparation thereof. A solid dispersion is characterized in that revaprazan particles are surface-modified with a water-soluble polymer, a water-soluble saccharide, a surfactant, or a mixture thereof. A pharmaceutical composition comprises the solid dispersion and a pharmaceutically acceptable carrier. A method for preparing the solid dispersion comprises the steps of: (a) suspending revaprazan and one of a water-soluble polymer, a water-soluble saccharide, a surfactant, and a mixture thereof in water to obtain a suspension; and (b) drying the suspension.
|
